APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody Anti-VEGF Ophthalmic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Analysis and Forecast 2026-2032

27 December 2025196 pages

Choose your research edition.

Industry ResearchMonoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Growth and Trends Forecast to 203275 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032178 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs include Coherus BioSciences, Roche and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales, projected growth trends, production technology, application and end-user industry.

Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Company

Coherus BioSciences

Roche

Novartis

Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Type

Brolucizumab

Faricimab

Brolucizumab

Other

Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Application

Age-related Macular Degeneration

Diabetic Retinopathy

Other

Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Brolucizumab Major Manufacturers Table 3. Faricimab Major Manufacturers Table 4. Brolucizumab Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Age-related Macular Degeneration Major Manufacturers Table 8. Diabetic Retinopathy Major Manufacturers Table 9. Other Major Manufacturers Table 10. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Trends Table 11. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Drivers Table 12. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Opportunities and Challenges Table 13. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Restraints Table 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021-2026) Table 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2027-2032) Table 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2026) & (K Units) Table 21. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2027-2032) & (K Units) Table 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021-2026) Table 23. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2027-2032) Table 24. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021-2026) Table 28. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers, Product Type & Application Table 32. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021-2026) Table 39. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2027-2032) Table 40. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units) Table 42. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2027-2032) & (K Units) Table 43. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026) Table 44. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2027-2032) Table 45. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2021-2026) & (US$/Unit) Table 46. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2027-2032) & (US$/Unit) Table 47. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021-2026) Table 51. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2027-2032) Table 52. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units) Table 54. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2027-2032) & (K Units) Table 55. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2026) Table 56. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2027-2032) Table 57. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2021-2026) & (US$/Unit) Table 58. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2027-2032) & (US$/Unit) Table 59. Coherus BioSciences Company Information Table 60. Coherus BioSciences Business Overview Table 61. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio Table 63. Coherus BioSciences Recent Development Table 64. Roche Company Information Table 65. Roche Business Overview Table 66. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio Table 68. Roche Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio Table 73. Novartis Recent Development Table 74. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 75. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 76. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units) Table 77. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2027-2032) & (K Units) Table 78. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 79. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 80. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 81. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 82. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units) Table 83. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2027-2032) & (K Units) Table 84. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 85. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 86. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 88. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 89. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 90. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units) Table 91. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2027-2032) & (K Units) Table 92. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 93. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 94. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 95. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 96. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 97. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units) Table 100. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2027-2032) & (K Units) Table 101. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 102. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 103. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 104. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 105. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units) Table 106. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2027-2032) & (K Units) Table 107. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 108. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 109. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 111. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 112. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 113. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units) Table 114. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2027-2032) & (K Units) Table 115. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 116. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 117. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 118. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 119. U.K. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 120. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 121. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 122. Spain Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 123. Netherlands Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 124. Switzerland Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 125. Sweden Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 126. Poland Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 127. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 128. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 129. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units) Table 130. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2027-2032) & (K Units) Table 131. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 132. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 133. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 134. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 135. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units) Table 136. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2027-2032) & (K Units) Table 137. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 138. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 139. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 140. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 141. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units) Table 142. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2027-2032) & (K Units) Table 143. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 144. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 145. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 146. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 147. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units) Table 148. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2027-2032) & (K Units) Table 149. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 150. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 151. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 153. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 154. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 155. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units) Table 156. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2027-2032) & (K Units) Table 157. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 158. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 159. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 160. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 161. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 162. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 163. Taiwan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 164. Southeast Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 165. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 166. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 167. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units) Table 168. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2027-2032) & (K Units) Table 169. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 170. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 171. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 172. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 173. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units) Table 174. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2027-2032) & (K Units) Table 175. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 176. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 177. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 178. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 179. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 180. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 181. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units) Table 182. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2027-2032) & (K Units) Table 183. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 184. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 185. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 186. Argentina Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 187. Chile Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 188. Colombia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 189. Peru Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 190. Saudi Arabia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 191. Israel Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 192. UAE Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 193. Turkey Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 194. Iran Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 195. Egypt Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Table 196. Key Raw Materials Table 197. Raw Materials Key Suppliers Table 198. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors List Table 199. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customers List Table 200. Research Programs/Design for This Report Table 201. Authors List of This Report Table 202. Secondary Sources Table 203. Primary Sources List of Figures Figure 1. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Image Figure 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Brolucizumab Image Figure 5. Faricimab Image Figure 6. Brolucizumab Image Figure 7. Other Image Figure 8. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Age-related Macular Degeneration Image Figure 11. Diabetic Retinopathy Image Figure 12. Other Image Figure 13. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (2021-2032) & (US$ Million) Figure 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021-2032) Figure 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (2021-2032) & (K Units) Figure 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales YoY (2021-2032) & (K Units) Figure 22. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales YoY (2021-2032) & (K Units) Figure 23. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales YoY (2021-2032) & (K Units) Figure 26. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021-2032) Figure 32. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2032) Figure 35. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021-2032) Figure 38. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2032) Figure 41. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Type (2021-2032) Figure 42. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Type (2021-2032) Figure 43. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Application (2021-2032) Figure 44. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Application (2021-2032) Figure 45. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Country (2021-2032) Figure 46. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Country (2021-2032) Figure 47. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Type (2021-2032) Figure 48. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Type (2021-2032) Figure 49. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Application (2021-2032) Figure 50. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Application (2021-2032) Figure 51. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Country (2021-2032) Figure 52. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Country (2021-2032) Figure 53. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Type (2021-2032) Figure 54. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Type (2021-2032) Figure 55. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Application (2021-2032) Figure 56. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Application (2021-2032) Figure 57. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Type (2021-2032) Figure 58. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Type (2021-2032) Figure 59. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Application (2021-2032) Figure 60. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Application (2021-2032) Figure 61. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Country (2021-2032) Figure 62. Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Country (2021-2032) Figure 63. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Type (2021-2032) Figure 64. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Type (2021-2032) Figure 65. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Application (2021-2032) Figure 66. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Application (2021-2032) Figure 67. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Country (2021-2032) Figure 68. SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Country (2021-2032) Figure 69. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Brolucizumab
  • Faricimab
  • Brolucizumab
  • Other
Applications
  • Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Other
Companies covered
  • Coherus BioSciences
  • Roche
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Type
  3. 1.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Brolucizumab
  5. 1.2.3 Faricimab
  6. 1.2.4 Brolucizumab
  7. 1.2.5 Other
  8. 1.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Application
  9. 1.3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Age-related Macular Degeneration
  11. 1.3.3 Diabetic Retinopathy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Dynamics
  1. 2.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Trends
  2. 2.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Drivers
  3. 2.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region
  3. 3.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region
  9. 3.4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Manufacturers
  2. 4.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Manufacturers
  6. 4.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market CR5 and HHI
  16. 4.8.2 2025 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Tier 1, Tier 2, and Tier 3
5 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Type
  1. 5.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type
  2. 5.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type
  6. 5.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type
6 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Application
  1. 6.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application
  2. 6.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application
  6. 6.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application
7 Company Profiles
  1. 7.1 Coherus BioSciences
  2. 7.1.1 Coherus BioSciences Company Information
  3. 7.1.2 Coherus BioSciences Business Overview
  4. 7.1.3 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
  6. 7.1.5 Coherus BioSciences Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
  18. 7.3.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Type
  2. 8.1.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2021-2032)
  5. 8.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Application
  6. 8.2.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2021-2032)
  9. 8.3 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country
  10. 8.3.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Type
  2. 9.1.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2021-2032)
  5. 9.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Application
  6. 9.2.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2021-2032)
  9. 9.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country
  10. 9.3.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Type
  2. 10.1.1 China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2021-2032)
  5. 10.2 China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Application
  6. 10.2.1 China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Type
  2. 11.1.1 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2021-2032)
  5. 11.2 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Application
  6. 11.2.1 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2021-2032)
  9. 11.3 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country
  10. 11.3.1 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Type
  2. 12.1.1 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Application
  6. 12.2.1 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country
  10. 12.3.1 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Value Chain Analysis
  2. 13.1.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Production Mode & Process
  6. 13.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors
  9. 13.2.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst